CRISPR-dCas13a-based electrochemical biosensor for sensitive detection of miR-331-5p as a potential biomarker of Parkinson's disease
Analytical Biochemistry · 2027
DOI: 10.1016/j.ab.2026.116260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Biochemistry, 2027. Verfasst von İrem Yiğit und 2 weiteren Autor:innen. Beteiligte Einrichtung: Kafkas University, Faculty of Medicine, Department of Physiology, Kars, Türkiye; Kafkas University, Faculty of Medicine, Department of Medical Bioche…. Hauptthemen laut MEDLINE: Biosensing Techniques, MicroRNAs, Electrochemical Techniques, Parkinson Disease. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Scientific and Technological Research Council of Turkey.
Abstract (Originalsprache)
This study aimed to develop a CRISPR-dCas13a-based electrochemical biosensor as a proof-of-concept analytical platform for the sensitive and selective detection of miR-331-5p, which has been reported to be associated with Parkinson's disease. The biosensor was prepared by sequentially forming a self-assembled monolayer with 11-mercaptoundecanoic acid (MUA) on a gold electrode, functionalizing the surface with a generation-4 polyamidoamine (PAMAM-G4) dendrimer, immobilizing dCas13a, and assembling the target-specific sgRNA recognition complex. The electrode-modification steps were evaluated using cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), Fourier transform infrared spectroscopy (FTIR), and scanning electron microscopy (SEM). The impedance response increased linearly with miR-331-5p concentration over the experimentally evaluated range of 5-400 pM. The limit of detection and limit of quantification were 7.82 and 23.71 pM, respectively. Responses to the non-target miRNAs miR-146a-5p, miR-19 b-3p, miR-24-3p, and miR-7-5p were substantially lower than the response to miR-331-5p. Triplicate spike-recovery measurements in healthy human serum and storage-stability studies supported the analytical applicability and reproducibility of the platform. These findings demonstrate a CRISPR-dCas13a/EIS-based proof-of-concept analytical platform for miR-331-5p detection. Validation in well-characterized clinical cohorts will be required before any diagnostic application can be established.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kafkas University, Faculty of Medicine, Department of Physiology, Kars, Türkiye; Kafkas University, Faculty of Medicine, Department of Medical Biochemistry, Kars, Türkiye.
- Kafkas University, Faculty of Medicine, Department of Physiology, Kars, Türkiye.
- Kafkas University, Faculty of Medicine, Department of Medical Biochemistry, Kars, Türkiye. Electronic address: onur.uygun@kafkas.edu.tr.
Förderung
- Scientific and Technological Research Council of Turkey
Zitieren
APA
Yiğit, İ., Azrak, B., & Uygun, Z. O. (2027). CRISPR-dCas13a-based electrochemical biosensor for sensitive detection of miR-331-5p as a potential biomarker of Parkinson's disease. Analytical Biochemistry. https://doi.org/10.1016/j.ab.2026.116260
Vancouver
Yiğit İ, Azrak B, Uygun ZO. CRISPR-dCas13a-based electrochemical biosensor for sensitive detection of miR-331-5p as a potential biomarker of Parkinson's disease. Analytical Biochemistry. 2027. doi:10.1016/j.ab.2026.116260
BibTeX
@article{Yiit2027,
author = {Yiğit, İrem and Azrak, Burcu and Uygun, Zihni Onur},
title = {CRISPR-dCas13a-based electrochemical biosensor for sensitive detection of miR-331-5p as a potential biomarker of Parkinson's disease},
journal = {Analytical Biochemistry},
year = {2027},
doi = {10.1016/j.ab.2026.116260}
}
EUVIMED